Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones?
TheFly reported on June 16 that JPMorgan upgraded CAMP4 to Overweight from Neutral and increased its price target to $9 from $5.
Camp4 Therapeutics Corp (CAMP)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Vivo Capital Albert Cha And Frank Kung | 4,246,568 | $18,557,502 | 1.69% | |
| 2. | Balyasny Asset Management Dmitry Balyasny | 2,575,724 | $11,255,914 | -3% | 0.01% |
| 3. | A16z Capital Management Marc Andreessen And Ben Horowitz | 2,125,339 | $9,287,731 | 0.07% | |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 1,960,784 | $8,568,626 | 0.01% | |
| 5. | Trails Edge Capital Partners Ortav (Tavi) Yehudai | 1,932,937 | $8,446,935 | -1% | 1.34% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.65 | 16,378 | $27,023.70 | 186,388 | 2026-08-03 | Filing | |
| $1.65 | 6,551 | $10,809.15 | 12,611 | 2026-08-03 | Filing | |
| $1.65 | 6,551 | $10,809.15 | 74,428 | 2026-08-03 | Filing | |
| $1.65 | 6,551 | $10,809.15 | 284,968 | 2026-08-03 | Filing | |
| $1.53 | 2,941,176 | $4,499,999.28 | 2,941,176 | 2025-09-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.50 | 10 | $45.00 | 2,433,270 | 2026-08-24 | Filing | |
| $4.50 | 32,018 | $144,081.00 | 2,433,280 | 2026-08-21 | Filing | |
| $4.54 | 114,700 | $520,738.00 | 2,465,298 | 2026-08-20 | Filing | |
| $4.76 | 45,147 | $214,899.72 | 2,579,998 | 2026-08-19 | Filing | |
| $4.76 | 1,738 | $8,272.88 | 0 | 2026-08-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,307,636 | $27,581,036 | 0.01% | |
| 2. | 5,869,091 | $25,647,928 | 8.91% | |
| 3. | 4,904,339 | $21,431,962 | 0% | |
| 4. | 1,644,134 | $7,184,865 | 0% | |
| 5. | 1,533,489 | $6,701,347 | 0% |
News See All
8 Best Up and Coming Pharmaceutical Stocks to Buy Now
Investors looking for substantial potential without making a sizable initial investment continue to be drawn to inexpensive stocks.
12 Penny Stocks with Insider Buying in 2025
Insider trading can be a reliable signal for gauging the degree of confidence that management has in the future of their company.
CalAmp Corp. (NASDAQ:CAMP) Q3 2024 Earnings Call Transcript
CalAmp Corp. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $-0.1.
Should You Exit CalAmp Corp. (CAMP)?
Aristotle Capital Boston, LLC, an investment advisor, released its “Small Cap Equity Strategy” third quarter 2023 investor letter. A copy of the same can be downloaded here.
CalAmp Corp. (NASDAQ:CAMP) Q2 2024 Earnings Call Transcript
Operator: Welcome to CalAmp's Second Quarter 2024 Financial Results Conference Call. My name is Cole, and I'll be the moderator for today's call.
CalAmp Corp. (NASDAQ:CAMP) Q1 2024 Earnings Call Transcript
Operator: Welcome to CalAmp's First Quarter 2024 Financial Results Conference Call. My name is Bethany, and I'll be the moderator for today's call.
CalAmp Corp. (NASDAQ:CAMP) Q4 2023 Earnings Call Transcript
Operator: Welcome to CalAmp's Fourth Quarter and Fiscal Year 2023 Financial Results Conference Call. My name is Tiya and I’ll be your moderator for today’s call.
Hedge Fund Resource Center